Structure-based drug design.

Most of the techniques used in structure-based drug design have experienced significant improvements in the past few years, resulting in a marked enhancement of the speed and the efficacy of this approach. At the same time, it was thought that the future of drug design lay in strategies involving solely combinatorial chemistry. It is becoming evident, however, that the development of future drugs will use a combination of methods that will contain a major component of structure-based design.

[1]  M. Levitt.  Accurate modeling of protein conformation by automatic segment matching. , 1992, Journal of molecular biology.

[2]  Yvonne C. Martin,et al.  ALADDIN: An integrated tool for computer-assisted molecular design and pharmacophore recognition from geometric, steric, and substructure searching of three-dimensional molecular structures , 1989, J. Comput. Aided Mol. Des..

[3]  A Itai,et al.  Confirmation of usefulness of a structure construction program based on three-dimensional receptor structure for rational lead generation. , 1993, Journal of medicinal chemistry.

[4]  William Fisanick,et al.  Experimental system for similarity and 3D searching of CAS registry substances. 1. 3D substructure searching , 1993, J. Chem. Inf. Comput. Sci..

[5]  Dinesh V. Patel,et al.  Strategy and Tactics in Combinatorial Organic Synthesis. Applications to Drug Discovery , 1996 .

[6]  C A Kettner,et al.  Structure-based understanding of ligand affinity using human thrombin as a model system. , 1996, Biochemistry.

[7]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[8]  R C Wade,et al.  'Flu' and structure-based drug design. , 1997, Structure.

[9]  Jackson Rc,et al.  Contributions of protein structure-based drug design to cancer chemotherapy. , 1997 .

[10]  L. Mario Amzel,et al.  Modeling the variable region of immunoglobulins , 1992 .

[11]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[12]  Chris M. W. Ho,et al.  FOUNDATION: A program to retrieve all possible structures containing a user-defined minimum number of matching query elements from three-dimensional databases , 1993, J. Comput. Aided Mol. Des..

[13]  K. P. Murphy,et al.  Structural energetics of peptide recognition: Angiotensin II/antibody binding , 1993, Proteins.

[14]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[15]  S. Doublié.  [29] Preparation of selenomethionyl proteins for phase determination. , 1997, Methods in enzymology.

[16]  M. Murcko,et al.  GroupBuild: a fragment-based method for de novo drug design. , 1993, Journal of medicinal chemistry.

[17]  T. Blundell,et al.  Knowledge based modelling of homologous proteins, Part I: Three-dimensional frameworks derived from the simultaneous superposition of multiple structures. , 1987, Protein engineering.

[18]  J. Spurlino,et al.  Serendipity meets precision: the integration of structure-based drug design and combinatorial chemistry for efficient drug discovery. , 1997, Structure.

[19]  L M Amzel,et al.  Loss of translational entropy in binding, folding, and catalysis , 1997, Proteins.

[20]  G J Williams,et al.  The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1977, Journal of molecular biology.

[21]  S. Prigge,et al.  Structure conservation in lipoxygenases: Structural analysis of soybean lipoxygenase‐1 and modeling of human lipoxygenases , 1996, Proteins.

[22]  Steven E. Ealick,et al.  Synchrotron beamlines for macromolecular crystallography , 1993 .

[23]  I. Kuntz,et al.  Automated docking with grid‐based energy evaluation , 1992 .

[24]  D. Goodsell,et al.  Automated docking of substrates to proteins by simulated annealing , 1990, Proteins.

[25]  S. P. Fodor,et al.  Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions. , 1994, Journal of medicinal chemistry.

[26]  M. Lawrence,et al.  CLIX: A search algorithm for finding novel ligands capable of binding proteins of known three‐dimensional structure , 1992, Proteins.

[27]  S. Freer,et al.  Design of enzyme inhibitors using iterative protein crystallographic analysis. , 1991, Journal of medicinal chemistry.

[28]  Joyce,et al.  Combinatorial chemistry searching for a winning combination , 1997, Current opinion in chemical biology.

[29]  A T Brünger,et al.  Three-dimensional structure of an angiotensin II-Fab complex at 3 A: hormone recognition by an anti-idiotypic antibody. , 1992, Science.

[30]  Wayne A Hendrickson,et al.  [28] Phase determination from multiwavelength anomalous diffraction measurements. , 1997, Methods in enzymology.

[31]  T. Blundell.  Structure-based drug design. , 1996, Nature.

[32]  P Willett,et al.  Docking small-molecule ligands into active sites. , 1995, Current opinion in biotechnology.

[33]  I. Campbell,et al.  NMR at very high fields. , 1994, Structure.

[34]  Gebhard F. X. Schertler,et al.  Overproduction of membrane proteins , 1992 .

[35]  I. Luque,et al.  Structure-based thermodynamic analysis of HIV-1 protease inhibitors. , 1997, Biochemistry.

[36]  H Liu,et al.  Rapid non-empirical approaches for estimating relative binding free energies. , 1995, Acta biochimica Polonica.

[37]  Hans-Joachim Böhm,et al.  The computer program LUDI: A new method for the de novo design of enzyme inhibitors , 1992, J. Comput. Aided Mol. Des..

[38]  S Vajda,et al.  Empirical free energy as a target function in docking and design: application to HIV‐1 protease inhibitors , 1996, FEBS letters.

[39]  J. Pflugrath,et al.  Developments in X-ray detectors , 1992, Current Biology.

[40]  T. Lybrand.  Ligand-protein docking and rational drug design. , 1995, Current Opinion in Structural Biology.

[41]  L M Amzel,et al.  Calculating three‐dimensional changes in protein structure due to amino‐acid substitutions: The variable region of immunoglobulins , 1986, Proteins.

[42]  L M Amzel,et al.  Estimation of changes in side chain configurational entropy in binding and folding: General methods and application to helix formation , 1994, Proteins.

[43]  C L Verlinde,et al.  Structure-based drug design: progress, results and challenges. , 1994, Structure.

[44]  J. S. Dixon,et al.  Evaluation of the CASP2 docking section , 1997, Proteins.

[45]  Timothy F. Havel,et al.  A new method for building protein conformations from sequence alignments with homologues of known structure. , 1991, Journal of molecular biology.

[46]  A. Pardi,et al.  Isotope labelling for NMR studies of biomolecules , 1992 .

[47]  I. Luque,et al.  Structure‐based thermodynamic design of peptide ligands: Application to peptide inhibitors of the aspartic protease endothiapepsin , 1998, Proteins.

[48]  K. P. Murphy,et al.  Entropy in biological binding processes: Estimation of translational entropy loss , 1994, Proteins.

[49]  Keith D. Watenpaugh,et al.  Macromolecular crystallography at cryogenic temperatures: Current Opinion in Structural Biology 1991, 1: 1012–1015 , 1991 .

[50]  M. Wolff,et al.  Antibody-directed drug discovery , 1990, Nature.

[51]  V. Hilser,et al.  The magnitude of the backbone conformational entropy change in protein folding , 1996, Proteins.

[52]  M. J. Gardner,et al.  COMBINATORIAL SYNTHESIS : THE DESIGN OF COMPOUND LIBRARIES AND THEIR APPLICATION TO DRUG DISCOVERY , 1995 .